Abstract
Clinical data suggest that the use of adjuvant tamoxifen citrate (Nolvadex) for a minimum of 5 years, and possibly indefinitely, will result in maximal antitumor benefit. There is concern that long-term tamoxifen maintenance therapy may result in the induction of drug resistance. This article reviews the potential molecular mechanisms of resistance to tamoxifen and explores the possibility of tamoxifen-stimulated tumor growth.
Original language | English (US) |
---|---|
Pages (from-to) | 1187-1191 |
Number of pages | 5 |
Journal | Archives of Surgery |
Volume | 128 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1993 |
Externally published | Yes |
ASJC Scopus subject areas
- Surgery